Peregrine Pharmaceuticals

  • Can Avastin’s Shortcomings Open the Door for Del Mar Pharmaceuticals?

    By Craig Keolanui - June 14, 2013 | Tickers: MRK, PPHM, RHHBY, TEVA

    The effectiveness of Genentech and Roche's (RHHBY.OB) glioblastoma multiforme (GBM) treatment, Avastin, has recently been challenged raising concerns from physicians and patients alike that a huge void in patient care can develop if the FDA decides to revoke Avastin's approval for treating GBM. GBM is one of the hardest indications of cancer to treat with a median survival of about 4.5 months without treatment and less more »

  • What’s Moving These Biotech Stocks?

    By Brian Nichols - February 12, 2013 | Tickers: NVO, PPHM, REGN, SNY

    Typically, it doesn't take a lot for a stock to trade with gains/losses of more than 5% in a session; it can be caused by an analyst's remarks, sometimes it's caused by earnings, or maybe it’s just a technical response. Sometimes the moves are warranted and other times they are not. Therefore, I am looking at several moves to determine if the stocks are presenting more »

  • 50% Upside on this Biotechnology Stock

    By Mohsin Saeed - February 7, 2013 | Tickers: PPHM, PFE, TEVA

    Editor's Note: The original article references one of Peregrine's drugs as Contara, the correct spelling is Cotara. This version has been corrected and Motley Fool apologizes for the error.

    The patent cliff has positively impacted the valuations of small biopharmaceutical companies due to their acquisition potential. Peregrine Pharmaceutical (NASDAQ: PPHM) is currently trading at a 50% discount to my estimated target price of $4. I believe the stock more »

  • The Good, The Bad, and The Ugly with The Medicines Company

    By Josef Ray Dagatan - January 17, 2013 | Tickers: CELG, PPHM, MDCO

    After the extravagant flair of celebrating Thanksgiving, Christmas, and New Year wears off, it’s common for a lot of people to pay more keen attention to their health. After all, when the guests have left and the parties are over, you tend to notice that you gained more than just a few unwanted pounds; you also increased your chances of getting sick and acquiring illnesses. In my opinion, being more »

  • Monday’s Most Significant Movers & the Meaning to Such Movement

    By Brian Nichols - January 8, 2013 | Tickers: MCP, NSM, PPHM, SCTY, VVUS

    The market fell nearly 0.50% on Monday after reaching multi-year highs. However, this period of profit taking did not slow a group of stocks that traded considerably higher behind numerous key developments. In this article I am looking at these stocks, determining why they moved, and how investors might want to play the news.



    1/7/13 Performance*

    Peregrine Pharmaceuticals




    (NASDAQ: VVUSmore »)

  • Is the Risk Worth the Reward for Biotech’s Most Volatile?

    By Brian Nichols - December 1, 2012 | Tickers: ACUR, PPHM, PFE

    An investment in a biotechnology stock can sometimes feel like a game of poker. It’s volatile, uncertain, and even when you think you have a winning hand, sometimes you’re disappointed. After several bad hands with both Peregrine Pharmaceuticals (NASDAQ: PPHM) and Acura Pharmaceuticals (NASDAQ: ACUR) both stocks have finally begun to trend higher. However, you must now ask yourself if the rally is just another eventual fold, and more »